Nexium Direct: AstraZeneca’s Ambitious Test Of Direct-To-Consumer Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Nexium will ship directly to patients as the drug is about to become victim to generic competition, signaling AstraZeneca’s satisfaction with its Arimidex program.
You may also be interested in...
Sun’s Ranbaxy Buy Out Could Have Implications For Nexium Generics
Ranbaxy’s ability to launch generic versions of AstraZeneca’s blockbuster Nexium in the U.S. on May 27 was uncertain already. Sun’s proposed $4 billion acquisition of Ranbaxy could further distract the troubled Indian generics firm from achieving that goal.
Teva’s Generic Viagra Launch Will Be Offset By Generic Cialis
Patent settlement will enable Teva to enter the market more than three years before Viagra’s use patent expires; Pfizer suddenly parts ways with General Counsel Amy Schulman.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.